Cytochrome P450 Inhibiting/inducing Medication Use among Patients with Advanced Ovarian Cancer Who Receive or Are Eligible for Poly (Adp-Ribose) Polymerase Inhibitors As First Line Maintenance Therapy (2200)
Gynecologic oncology（2023）
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要